Neal A Deluca

US Patent:

7078029, Jul 18, 2006

Filed:

May 1, 2003

Appl. No.:

10/427739

Inventors:

Neal A. DeLuca - Cheswick PA, US

Assignee:

University of Pittsburgh of the Commonwealth System of Higher Education - Pittsburgh PA

International Classification:

A61K 48/00
C12N 15/00
C12N 15/64

US Classification:

424 932, 4353201, 435325, 435 9141, 435 9142, 435455

Abstract:

The present invention provides an HSV having a genome with a mutation of a TAATGARAT sequence such that, in the presence of a ICP4 gene product, a native immediate early gene is expressed from the genome with delayed kinetics, the genome having a further inactivating mutation of each of the genes encoding ICP4.

US Patent:

20010026799, Oct 4, 2001

Filed:

Apr 10, 2001

Appl. No.:

09/829839

Inventors:

Neal DeLuca - Cheswick PA, US

International Classification:

A61K039/12
C12N007/01
C12N015/86

US Classification:

424/199100, 435/456000, 435/235100

Abstract:

The present invention provides an HSV having a genome with a mutation of a TAATGARAT sequence such that, in the presence of a ICP4 gene product, a native immediate early gene is expressed from the genome with delayed kinetics, the genome having a further inactivating mutation of each of the genes encoding ICP4.

US Patent:

58799346, Mar 9, 1999

Filed:

Jun 7, 1995

Appl. No.:

8/479024

Inventors:

Neal A. DeLuca - Cheswick PA

Assignee:

University of Pittsburgh of the Commonwealth System of Higher Education - Pittsburgh PA

International Classification:

C12N 1586

US Classification:

4353201

Abstract:

Cell lines that express complementing levels of herpes simplex virus (HSV) essential immediate early proteins ICP4 and ICP27 and a method of producing the novel cell lines are disclosed. These cell lines are utilized to provide HSV strains deficient for both ICP4 and ICP27, and their generation, and HSV strains deficient for ICP4 and ICP27 and one or more additional genes, and their generation. Vectors are provided from these methods of using these HSV strains for gene transfer and for producing site-specific homologous recombination with cellular DNA.

US Patent:

56587244, Aug 19, 1997

Filed:

Nov 21, 1994

Appl. No.:

8/342795

Inventors:

Neal A. DeLuca - Cheswick PA

Assignee:

University of Pittsburgh of the Commonwealth System of Higher Education - Pittsburgh PA

International Classification:

C12Q 170
C12N 704
C12N 510
C12N 1586

US Classification:

435 5

Abstract:

Novel cell lines that express complementing levels of herpes simplex virus (HSV) essential immediate early proteins ICP4 and ICP27 and a method of producing the novel cell lines. These novel cell lines are utilized to provide novel HSV strains deficient for both ICP4 and ICP27, and their generation, and novel HSV strains deficient for ICP4 and ICP27 and one or more additional genes, and their generation. Vectors are provided from these methods of using these vectors for gene transfer and for producing site-specific homologous recombinations with cellular DNA.

US Patent:

62615521, Jul 17, 2001

Filed:

Nov 20, 1998

Appl. No.:

9/194274

Inventors:

Neal A. DeLuca - Cheswick PA

Assignee:

University of Pittsburgh of the Commonwealth System of Higher Education - Pittsburgh PA

International Classification:

A61K 4800
C12N 1500
C12N 1588

US Classification:

424 932

Abstract:

The present invention provides an HSV having a genome from which, in the presence of the ICP4 gene product, a native immediate early gene is expressed with delayed kinetics, and an HSV having a genome with a mutation in each of the genes encoding ICP4, ICP27, and another HSV gene; preferably such HSV have one or more exogenous genes. The present invention further provides a method of expressing a polynucleotide within a cell comprising infecting the cell with such an HSV. Furthermore, the present invention provides a cell line having DNA encoding the HSV proteins ICP4, ICP27, and ICP0, and a method of producing an HSV vector by employing such a cell line.

US Patent:

58692347, Feb 9, 1999

Filed:

Jan 5, 1996

Appl. No.:

8/583569

Inventors:

David M. Knipe - Auburndale MA
Kai Xia - Allston MA
Neal A. DeLuca - Cheswick PA

Assignee:

President and Fellows of Harvard College - Cambridge MA

International Classification:

C12Q 170
G01N 33567

US Classification:

435 5

Abstract:

The present invention relates to a method of identifying a compound which modulates (enhances, inhibits, reduces) herpesvirus infection of a vertebrate cell comprising the steps of combining a phosphorylating enzyme capable of catalyzing the phosphorylation of ICP4, a substrate comprising a polypeptide which is phosphorylated by the enzyme, a phosphate source and the compound to be assessed; maintaining the combination under conditions appropriate for phosphorylation of the substrate; and determining phosphorylation of the substrate which occurs in the presence of the compound to be assessed. The present invention also relates to the compounds identified by the methods of the present invention.

US Patent:

58044132, Sep 8, 1998

Filed:

May 22, 1996

Appl. No.:

8/651419

Inventors:

Neal A. DeLuca - Cheswick PA

Assignee:

University of Pittsburgh of the Commonwealth System of Higher Education - Pittsburgh PA

International Classification:

C12N 506
C12N 704
C12N 1509
C12N 1586

US Classification:

435 691

Abstract:

Cell lines that express complementing levels of herpes simplex virus (HSV) essential immediate early proteins ICP4 and ICP27 as well as ICP4, ICP27 and ICP0 and a method of producing the novel cell lines are disclosed. These cell lines are utilized to provide HSV strains deficient for both (a) ICP4 and ICP27; (b) ICP4, ICP27, ICP22; (c) ICP4, ICP27, ICP0; and, (d) ICP4, ICP27, ICP22 and ICP0, and their generation, and HSV strains deficient for (a) ICP4 and ICP27; (b) ICP4, ICP27, ICP22; (c) ICP4, ICP27, ICP0; and, (d) ICP4, ICP27, ICP22 and ICP0, and one or more additional genes, and their generation. Vectors are provided from these methods of using these HSV strains for gene transfer and for producing site-specific homologous recombination with cellular DNA.